GSK Investigational Site

Lecce, Apulia 73100

0 studies enrolling now · 2 studies all time

What they study most

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Neoplasms, Breast, Ovarian Neoplasms

Studies at this site

• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients — Stopped early
• Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer — Completed